{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:59:02Z","timestamp":1789689542059,"version":"4.0.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1365,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1111\/j.1365-2133.2011.10660.x","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T18:20:07Z","timestamp":1317666007000},"page":"389-398","source":"Crossref","is-referenced-by-count":53,"title":["A randomized, placebo- and active-controlled, parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis"],"prefix":"10.1093","volume":"166","author":[{"given":"B.","family":"Elewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Rich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schlessinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Tavakkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,12,6]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1517\/13543784.16.2.157","article-title":"Recent progress on the topical therapy of onychomycosis","volume":"16","author":"Alley","year":"2007","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1067\/mjd.2000.107754","article-title":"A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns","volume":"43","author":"Ghannoum","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.0933-7407.2003.00933.x","article-title":"High prevalence of foot diseases in Europe: results of the Achilles Project","volume":"46","author":"Burzykowski","year":"2003","journal-title":"Mycoses"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/CMR.11.3.415","article-title":"Onychomycosis: pathogenesis, diagnosis, and management","volume":"11","author":"Elewski","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1468-3083.2004.01136.x","article-title":"The effects of foot disease on quality of life: results of the Achilles Project","volume":"19","author":"Katsambas","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0190-9622(96)90061-4","article-title":"Onychomycosis: a significant medical disorder","volume":"35","author":"Scher","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0190-9622(98)70199-9","article-title":"Effect of onychomycosis on quality of life","volume":"38","author":"Drake","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-4362.1997.00163.x","article-title":"The effect of toenail onychomycosis on patient quality of life","volume":"36","author":"Elewski","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2230.1997.tb02626.x","article-title":"The impact of onychomycosis on quality of life","volume":"22","author":"Whittam","year":"1997","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB10|cit10","volume-title":"Lamisil\u00ae (terbinafine hydrochloride) tablets [prescribing information]","author":"Novartis Pharmaceuticals","year":"2005"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB11|cit11","volume-title":"Sporanox\u00ae (itraconazole) capsules [prescribing information]","author":"Janssen Pharmaceutical","year":"2006"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1529-8019.2007.00109.x","article-title":"Toenail onychomycosis: current and future treatment options","volume":"20","author":"Finch","year":"2007","journal-title":"Dermatol Ther"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB13|cit13","volume-title":"Penlac\u00ae nail lacquer (ciclopirox) topical solution, 8% [prescribing information]","author":"Dermik Laboratories","year":"2006"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1067\/mjd.2000.109071","article-title":"Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis","volume":"43","author":"Gupta","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB15|cit15","first-page":"302","article-title":"The use of terbinafine in the treatment of onychomycosis in adults and special populations: a review of the evidence","volume":"4","author":"Gupta","year":"2005","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjopharm.2005.12.012","article-title":"Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial","volume":"4","author":"Tavakkol","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7547\/0960465","article-title":"Treatment of toenail onychomycosis with oral terbinafine plus aggressive debridement: IRON-CLAD, a large, randomized, open-label, multicenter trial","volume":"96","author":"Jennings","year":"2006","journal-title":"J Am Podiatr Med Assoc"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB18|cit18","unstructured":"SP Europe Noxafil 40\u2003mg\/ml oral suspension [summary of product characteristics] SP Europe 2010"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB19|cit19","volume-title":"Noxafil\u00ae (posaconazole) oral suspension [prescribing information]","author":"Schering Corporation","year":"2010"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2165\/00003495-200565110-00007","article-title":"Posaconazole","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1086\/503425","article-title":"Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB25|cit25","volume-title":"Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE)","author":"National Cancer Institute","year":"2006"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","article-title":"Hy\u2019s law: predicting serious hepatotoxicity","volume":"15","author":"Temple","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1540-9740.2005.03435.x","article-title":"Dermatophytosis: the management of fungal infections","volume":"4","author":"Gupta","year":"2005","journal-title":"Skinmed"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1080\/13693780410001731583","article-title":"In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species","volume":"43","author":"Gupta","year":"2005","journal-title":"Med Mycol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2133.1999.00008.x","article-title":"LION Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. itraconazole in onychomycosis","volume":"141","author":"Sigurgeirsson","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1128\/JCM.39.11.4208-4209.2001","article-title":"In vitro activity of posaconazole against clinical isolates of dermatophytes","volume":"39","author":"Barchiesi","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1468-3083.2005.01286.x","article-title":"Clinical trial design - towards better practices","volume":"19","author":"Correia","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB32|cit32","first-page":"121","article-title":"In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature","volume":"20","author":"Espinel-Ingroff","year":"2003","journal-title":"Rev Iberoam Micol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB33|cit33","volume-title":"British National Formulary","author":"BMJ Group","year":"2011"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0190-9622(00)90129-4","article-title":"Onychomycosis caused by nondermatophytic molds: clinical features and response to treatment of 59 cases","volume":"42","author":"Tosti","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200038020-00002","article-title":"Effects of the antifungal agents on oxidative drug metabolism: clinical relevance","volume":"38","author":"Venkatakrishnan","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1111\/j.1365-2133.2011.10660.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10660.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10660.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T13:53:47Z","timestamp":1676382827000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/166\/2\/389\/6613688"}},"subtitle":["Toenail onychomycosis: treatment with posaconazole"],"short-title":[],"issued":{"date-parts":[[2011,12,6]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10660.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12,6]]}}}